![]() |
PCDVD¼Æ¦ì¬ì§Þ°Q½×°Ï
(https://www.pcdvd.com.tw/index.php)
- ¤C¼L¤K¦Þ²§¨¥°ó
(https://www.pcdvd.com.tw/forumdisplay.php?f=12)
- - °ªºÝ¬Ì]º4§å§¹¦¨ÀËÅç«Ê½p 26.5¸U¾¯³Ä±ß©ñ¦æ
(https://www.pcdvd.com.tw/showthread.php?t=1188037)
|
|---|
§R...
«áÄò¦A¸É |
¤Þ¥Î:
À˹î©xªº¤£°_¶D»¡©ú®ÑÁÙÆZ¦n¯ºªº¡A¥un¦Y¹L¦³µÜ¾¯¹}®Æªº¤û´N¥i¥HºÙµÜ¤û¡A¨º¥þ¥xÆW¦³¦Y¹L¤û¦×ªº®t¤£¦h³£¬OµÜ¤H¤F¡A§O§Ñ°O¥xÆW¤û¦×µ´¤j³¡¤À¥õ¿à¶i¤f |
½Ð°Ý§A¬On³Q¥´Áy, ÁÙ¬On³Q¥´Äýw...? :confused:
³o½gÀ³¸ÓÁÙ¦³ "¹w¦L¥»", n³Q¥´ÁyÁÙ¬O³Q¥´Äýwªº±z¥i¥H¥h§ä¥X¨Ó¬Ý¬Ý¡C --- Other key findings from the study: ¡CA single dose of the Moderna vaccine has similar or greater effectiveness against the Delta variant as single doses of the other vaccines. ¡CTwo doses of Pfizer-BioNTech have greater initial effectiveness against new COVID-19 infections, but this declines faster compared with two doses of Oxford-AstraZeneca. ¡CResults suggest that after four to five months effectiveness of these two vaccines would be similar ¡V however, researchers say long-term effects need to be studied. ¡CThe time between doses does not affect effectiveness in preventing new infections, but younger people have even more protection from vaccination than older people. --- ¬ã¨sªº¨ä¥L¥Dnµo²{¡G ¡C³æ¾¯ Moderna ¬Ì]¹ï Delta ÅÜÅ骺¦³®Ä©Ê»P³æ¾¯¨ä¥L¬Ì]¬Û¦ü©Î§ó°ª¡C ¡C¨â¾¯½÷·ç-BioNTech ¹ï·sªº COVID-19 ·P¬V¨ã¦³§ó¤jªºªì©l¦³®Ä©Ê¡A¦ý»P¨â¾¯¤û¬z-ªü´µ§Q±d¬Û¤ñ¡A³oºØ¤U°³t«×§ó§Ö¡C ¡Cµ²ªGªí©ú¡A³o¨âºØ¬Ì]¦b¥|¨ì¤Ó¤ë«áªº®ÄªG±N¬Û¦ü¡X¡X¦ý¬O¡A¬ã¨s¤Hûªí¥Ü»Ýn¬ã¨sªø´Á¼vÅT¡C ¡C¨â¦¸±µºØ¤§¶¡ªº®É¶¡¶¡¹j¤£·|¼vÅT¹w¨¾·s·P¬Vªº¦³®Ä©Ê¡A¦ý»P¦Ñ¦~¤H¬Û¤ñ¡A¦~»´¤H¹ï¬Ì]±µºØªº«OÅ@¤O«×§ó¤j¡C --- ¤Þ¥Î:
|
¤Þ¥Î:
§A¥H¬°µÜ¾¯¬O¥Î§j½bªº? |
¤Þ¥Î:
³oÂǤf¤ñ¤Ñ¥ÍÁy¥Ö«pÁÙÄê , ¯u¦³¤H·|®³³o·íÂǤf¨Ó¥Î? ºÃ´b??? :confused: |
¯uªº°µ±o¦n, ¬°¦ó:
1. °µ±oºC. 2. ¸õµ{§Ç. 3. ¤£¨}«~°ª. ¦ý, À°¦£¸Ñµª. 1. ¬DÃøªº°µ. 2. ¦]¬°²{¦b±¡ªp«æ»Ý. 3. ³oÓ¥»¨Ó´N¬OÃø°µ. ... ¦³¤°»òº|±¼ªº¶Ü? === §Ú¨S·N¨£®³¤°»ò·íÂǤf, ¥un¤£¬O¹G¤H¥u¦³³oÓ¿ï¶µ´N¦n. ³á, ¹ï¤FÁÙ¦³§ï¼Ð·Ç. ¤£¹LÁÙ¬O¦Ñ¸Ü, ¨S·N¨£, ÀH«K, ¤£nÅܦ¨¥u¦³³oÓ¬Ì]¯à¥´´N¦n. |
¤Þ¥Î:
¥¦§j¤û§j²ßºD¤F¡A©Ò¥H¥u·|¥Î§j½â°Õ! :D :D :D |
¤Þ¥Î:
§A¥ý¥h¬Ý¬ÝÀ˹î©xªº¤£°_¶D®Ñ |
¤Þ¥Î:
»Õ¤U¬Ý°_¨Ó±Mªø¬°§j³â§a :like: |
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Varian
¤Þ¥Î«D¬Ì]¼tªº²Ä¤T¤è³Ì·s¬ã¨s¡]8/12¡^ Results: Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) was notably lower among persons with the delta variant (30.7%; 95% confidence interval [CI], 25.2 to 35.7) than among those with the alpha variant (48.7%; 95% CI, 45.5 to 51.7); the results were similar for both vaccines. With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among persons with the alpha variant and 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant. With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among persons with the alpha variant and 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant. ¹ïDELTAÅܺءABNT¤U°¤F5.7¢H¡AAZ¤U°¤F7.5¢H¡A |
| ©Ò¦³ªº®É¶¡§¡¬°GMT +8¡C ²{¦bªº®É¶¡¬O01:38 AM. |
vBulletin Version 3.0.1
powered_by_vbulletin 2025¡C